GlassScriptPhysician profile
Selma Prechel
NPI 1629252176
$2,200.73
in general payments reported to CMS, 2019-2025
20 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2021: $224 · 2022: $447 · 2023: $38.78 · 2024: $682 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $599 · Food and Beverage: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $599.00 |
| Food and Beverage | $581.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $599.00 | 2024 | Hemosphere |
| Janssen Pharmaceuticals, INC | $235.24 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $216.70 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $214.73 | 2023-2025 | Rexulti, Nuedexta |
| Janssen Biotech, INC. | $148.64 | 2025 | Carvykti, Rybrevant |
| Avanir Pharmaceuticals, INC. | $141.09 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $125.92 | 2022 | |
| Novartis Pharmaceuticals Corporation | $120.78 | 2019 | |
| Cequr Corporation | $117.92 | 2022 | |
| Alkermes, INC. | $45.09 | 2025 | Aristada, Lybalvi |
| Ucb, INC. | $41.98 | 2024 | Briviact |
| Lundbeck LLC | $33.38 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.96 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.59 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $24.22 | 2024 | Gemtesa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.82 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.96 | 2024 | Airsupra |
| Lilly USA, LLC | $14.83 | 2025 | Jardiance |
| Cipher Pharmaceuticals US LLC | $14.50 | 2025 | Spinosad, Natroba |
| Teva Pharmaceuticals USA, INC. | $14.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selma Prechel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.